Dr. Eskelund on Outcomes of TP53-Mutated MCL

Christian Winther Eskelund, MD
Published: Wednesday, Oct 11, 2017



Christian Winther Eskelund, MD, Copenhagen University Hospital, Rigshospitalet, discusses outcomes for patients with TP53-mutated mantle cell lymphoma (MCL).

The significant findings of a study investigating TP53 mutations were that patients who had TP53 mutations did far worse than patients who had no mutations, states Eskelund. The median overall survival was 1.8 years versus 12 years for non-mutated patients.

TP53 is normally associated with poor outcomes in hematologic malignancies, making this an expected outcome, according to Eskelund.
 
SELECTED
LANGUAGE


Christian Winther Eskelund, MD, Copenhagen University Hospital, Rigshospitalet, discusses outcomes for patients with TP53-mutated mantle cell lymphoma (MCL).

The significant findings of a study investigating TP53 mutations were that patients who had TP53 mutations did far worse than patients who had no mutations, states Eskelund. The median overall survival was 1.8 years versus 12 years for non-mutated patients.

TP53 is normally associated with poor outcomes in hematologic malignancies, making this an expected outcome, according to Eskelund.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x